Study of a Series of Patients Treated for Retrograde Cricopharyngeal Muscle Dysfunction Syndrome

Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Dec 14, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a condition called Retrograde Cricopharyngeal Dysfunction syndrome (R-CPD), which makes it difficult for some people to burp. This syndrome can lead to discomfort and other swallowing issues. The trial is specifically looking at patients who have received treatment with botulinum toxin injections into a muscle in the throat called the cricopharyngeus. This treatment aims to help relieve symptoms related to R-CPD.

To be eligible for this study, participants need to be at least 18 years old and have been diagnosed with R-CPD, having received the botulinum toxin treatment between January and December 2022. It's important for participants to agree to allow their medical data to be used for research purposes. Those who do participate can expect to contribute to understanding this condition better and potentially improve treatment options for others in the future. The study is currently recruiting participants of all genders, and it aims to help raise awareness of this lesser-known syndrome, especially in France.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Major subject (≥18 years old)
• • Subject treated by injection of botulinum toxin into the cricopharyngeal muscle after having had a diagnosis of R-CPD in consultation between January 1, 2022 and December 31, 2022
• • Subject not opposing the reuse of their data for the purposes of this research.
• Exclusion Criteria:
• • Subject having expressed opposition to participating in the study,
• • Subject under judicial protection
• • Subject under guardianship or curatorship